The delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate?
Abstract Background Tuberculosis (TB) remains a major cause of morbidity and mortality in people living with HIV (PLHIV). New TB vaccines may help reduce this burden. There is limited data on the response to new TB vaccines in PLHIV and how this may vary with levels of immunosuppression and anti-ret...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-025-11249-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849335082643357696 |
|---|---|
| author | Tom Sumner Rebecca A. Clark Tomos O. Prys-Jones Roel Bakker Gavin Churchyard Richard G. White |
| author_facet | Tom Sumner Rebecca A. Clark Tomos O. Prys-Jones Roel Bakker Gavin Churchyard Richard G. White |
| author_sort | Tom Sumner |
| collection | DOAJ |
| description | Abstract Background Tuberculosis (TB) remains a major cause of morbidity and mortality in people living with HIV (PLHIV). New TB vaccines may help reduce this burden. There is limited data on the response to new TB vaccines in PLHIV and how this may vary with levels of immunosuppression and anti-retroviral therapy (ART). The potential interaction between vaccine efficacy and ART raises questions about the optimum timing of vaccination against TB in PLHIV. Methods Using a simple cumulative risk model, we compared the impact of different TB vaccination strategies for PLHIV. We compared the impact of vaccinating at linkage to HIV care, to the impact of vaccinating at ART initiation. We explored how the optimum timing of vaccination depends on characteristics of the vaccine and the ART program at an individual and population level. Results For an individual, the optimum timing of vaccination against TB is at ART initiation unless the time to ART initiation is more than 6 months or if the reduction in vaccine efficacy when given prior to ART is small. At a population level, the proportion of PLHIV who initiate ART is a key determinate of the optimum strategy. If ART uptake is low, it would be better to vaccinate at linkage to HIV care, even if vaccine efficacy in ART naïve individuals is less than 50% of efficacy in individuals on ART. Conclusions Our results suggest that the optimum timing of new TB vaccination for PLHIV will depend on the relative efficacy of vaccination in ART-naïve individuals vs. individuals on ART, and the uptake and timing of ART initiation. If vaccine efficacy is lower among ART-naïve individuals, improvements in HIV programs may help maximize the impact of new TB vaccines. |
| format | Article |
| id | doaj-art-478ffec54d2549adbc40aedfa87ae028 |
| institution | Kabale University |
| issn | 1471-2334 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj-art-478ffec54d2549adbc40aedfa87ae0282025-08-20T03:45:24ZengBMCBMC Infectious Diseases1471-23342025-07-0125111010.1186/s12879-025-11249-yThe delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate?Tom Sumner0Rebecca A. Clark1Tomos O. Prys-Jones2Roel Bakker3Gavin Churchyard4Richard G. White5TB Modelling Group and TB Centre, London School of Hygiene and Tropical MedicineTB Modelling Group and TB Centre, London School of Hygiene and Tropical MedicineTB Modelling Group and TB Centre, London School of Hygiene and Tropical MedicineTB Modelling Group and TB Centre, London School of Hygiene and Tropical MedicineThe Aurum InstituteTB Modelling Group and TB Centre, London School of Hygiene and Tropical MedicineAbstract Background Tuberculosis (TB) remains a major cause of morbidity and mortality in people living with HIV (PLHIV). New TB vaccines may help reduce this burden. There is limited data on the response to new TB vaccines in PLHIV and how this may vary with levels of immunosuppression and anti-retroviral therapy (ART). The potential interaction between vaccine efficacy and ART raises questions about the optimum timing of vaccination against TB in PLHIV. Methods Using a simple cumulative risk model, we compared the impact of different TB vaccination strategies for PLHIV. We compared the impact of vaccinating at linkage to HIV care, to the impact of vaccinating at ART initiation. We explored how the optimum timing of vaccination depends on characteristics of the vaccine and the ART program at an individual and population level. Results For an individual, the optimum timing of vaccination against TB is at ART initiation unless the time to ART initiation is more than 6 months or if the reduction in vaccine efficacy when given prior to ART is small. At a population level, the proportion of PLHIV who initiate ART is a key determinate of the optimum strategy. If ART uptake is low, it would be better to vaccinate at linkage to HIV care, even if vaccine efficacy in ART naïve individuals is less than 50% of efficacy in individuals on ART. Conclusions Our results suggest that the optimum timing of new TB vaccination for PLHIV will depend on the relative efficacy of vaccination in ART-naïve individuals vs. individuals on ART, and the uptake and timing of ART initiation. If vaccine efficacy is lower among ART-naïve individuals, improvements in HIV programs may help maximize the impact of new TB vaccines.https://doi.org/10.1186/s12879-025-11249-yTuberculosisVaccinesHIVModelingAnti-retroviral therapy |
| spellingShingle | Tom Sumner Rebecca A. Clark Tomos O. Prys-Jones Roel Bakker Gavin Churchyard Richard G. White The delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate? BMC Infectious Diseases Tuberculosis Vaccines HIV Modeling Anti-retroviral therapy |
| title | The delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate? |
| title_full | The delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate? |
| title_fullStr | The delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate? |
| title_full_unstemmed | The delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate? |
| title_short | The delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate? |
| title_sort | delivery of new tuberculosis vaccines to people living with hiv when to vaccinate |
| topic | Tuberculosis Vaccines HIV Modeling Anti-retroviral therapy |
| url | https://doi.org/10.1186/s12879-025-11249-y |
| work_keys_str_mv | AT tomsumner thedeliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT rebeccaaclark thedeliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT tomosoprysjones thedeliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT roelbakker thedeliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT gavinchurchyard thedeliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT richardgwhite thedeliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT tomsumner deliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT rebeccaaclark deliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT tomosoprysjones deliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT roelbakker deliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT gavinchurchyard deliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate AT richardgwhite deliveryofnewtuberculosisvaccinestopeoplelivingwithhivwhentovaccinate |